Paper presented on 5th June at ASCO – by Bruce Sylvester – The antidepressant duloxetine (Cymbalta ®), relieves neuropathic pain caused by chemotherapy in 59 percent of patients,… read more.
by Bruce Sylvester – Researchers report that, in the last quarter of the 20th century, changes in smoking behaviors have led to a significant drop in lung cancer… read more.
Emerging uses of FDA Approved Drugs – by Bruce Sylvester – Researchers from a phase 2 study published on March 27 in The Lancet Oncology report that ipilimumab,… read more.
Taken from The Lancet – by Bruce Sylvester – Two papers published in March, 2012 in The Lancet suggest that daily aspirin use can be protective against cancer.
In order to promote the ongoing education in cancer care which is one of the objectives of the association the Cork branch holds an annual education update. In… read more.
Quality-of-life issues gaining prominence as long-term cancer survival rates increase. More than 80 percent of radiation oncologists discuss the impact of cancer treatments on fertility with their patients… read more.
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of… read more.
For the first time, researchers have successfully injected cultured red blood cells (cRBCs) created from human hematopoietic stem cells (HSCs) into a human donor, according to study results… read more.
Pictured: Dr. Yael P. Mosse is a pediatric oncologist at The Children’s Hospital of Philadelphia. Children’s Hospital of Philadelphia researcher leads trial of ALK inhibitor in neuroblastoma, lymphoma. … read more.
A key goal of MIRT is to train and mentor the clinician scientists of the future. An Interview with Dr. Peter O’Gorman, Consultant Haematologist, at the Mater University… read more.
A key goal of MIRT is to train and mentor the clinician scientists of the future. An Interview with Dr. Peter O’Gorman, Consultant Haematologist, at the Mater University… read more.
An investigational oral drug delayed disease relapse for nearly a year in some patients with advanced non-small cell lung cancer (NSCLC).
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
